Reduced plasma fibrinolytic potential in patients with recurrent implantation failure after IVF and embryo transfer

Human Reproduction

Volumn 26, Issue 3, 2011, Pages 510-516

  Martnez Zamora, M Angeles ^a   Creus, Montserrat ^a   Tassies, Dolors ^b   Reverter, Juan Carlos ^b   Civico, Salvadora ^a   Carmona, Francisco ^a   Balasch, Juan ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

clot lysis time; IVF; recurrent implantation failure; recurrent reproductive failure; thrombin activatable fibrinolysis inhibitor

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; EMBRYO TRANSFER; EUGLOBULIN LYSIS TEST; FEMALE; FERTILITY; FERTILIZATION IN VITRO; FIBRINOLYSIS; GENETIC POLYMORPHISM; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; PROSTHESIS FAILURE; PROTEIN BLOOD LEVEL; RECURRENT DISEASE;

EID: 79951564332     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deq369     Document Type: Article

References (48)

1. ACOG Practice Bulletin. Management of recurrent early pregnancy loss. Int J Gynecol Obstet 2002;78:179-190.
2. ACOG Committee Opinion No. 430. American College of Obstetricians and Gynecologists. Preimplantation genetic screening for aneuploidy. Obstet Gynecol 2009;113:766-767.
3. Bischof P, Aplin JD, Bentin-Ley U, Brannstrom M, Casslen B, Castrillo JL, Classen-Linke I, Critchley HO, Devoto L, D'Hooghe T. et al. Implantation of the human embryo: research lines and models. From the implantation research network 'Fruitful'. Gynecol Obstet Invest 2006;62:206-216. (Pubitemid 44763187)
4. Bjornsson TD, Schneider DE, Berger H. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989;250:154-161. (Pubitemid 19194985)
5. Bouma BN, Meijers JC. Thombin-activatablefibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypectidase U). J Thromb Haemost 2003;1:1566-1574.
6. Bulleti C, Flamigni C, Giacomucci E. Reproductive failure due to spontaneous abortion and recurrent miscarriage. Hum Reprod Update 1996;2:118-136. (Pubitemid 26173039)
7. Carmona F, Font J, Azulay M, Creus M, Fabregues F, Cerverea R, Puerto B, Balasch J. Risk factors associated with fetal losses in treated antiphospholipid śndrome pregnancies: a multivariate análisis. Am J Reprod Immunol 2001;46:274-279. (Pubitemid 32926908)
8. Christiansen OB, Nielsen HS, Kolte AM. Future directions of failed implantation and recurrent miscarriage research. Reprod Biomed Online 2006;13:71-83. (Pubitemid 44054848)
9. Choudhury SR, Knapp LA. Human reproductive failure. I: immunlogical factors. Hum Reprod Update 2000;7:113-134.
10. Clark DA, Coulam CB, Daya S, Chaouat G. Unexplained sporadic and recurrent miscarriage in the new millennium: a critical analysis of immune mechanisms and treatments. Hum Reprod Update 2001; 7:501-511. (Pubitemid 32827551)
11. Clark P, Walker ID, Langhorne P, Crichton L, Thomson A, Greaves M, Whyte S, Greer IA. SPIN: the Scottish Pregnancy Intervention Study: a multicentre randomised controlled trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood 2010;115:4162-4167.
12. Colucci M, Pentimone A, Binetti BM, Creamarossa M., Piro D, Semerano N. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin. Thromb Haemost 2002;88:282-287. (Pubitemid 34873710)
13. Coulam CB, Jeyendran RS. Thrombophilic gene polymorphisms are risk factors for unexplained infertility. Fertil Steril 2009;91:1516-1517.
14. Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online 2006;12:322-327.
15. Creus M, Calafell JM, Ćvico S, Fábregues F, Carmona F, Vanrell JA, Balasch J. Materno-fetal immunogenetic disparity: the biological basis for in vitro fertilization treatment in patients with unexplained recurrent abortion? Am J Reprod Immunol 2003;50:420-426. (Pubitemid 37351193)
16. Curnow JL, Morel-Kopp M-C, Roddie C, Aboud M, Ward CM. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost 2006;5:528-534. (Pubitemid 46680686)
17. El-Toukhy T, Taranissi M. Towards better quality research in recurrent implantation failure: standardizing its definition is the first step. Reprod Biomed Online 2006;12:383-385.
18. ′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thombosis. Haematologica 2001;86:510-517. (Pubitemid 33638980)
19. Gris JC, Ripart-Neveu S, Maugard C, Tailland ML, Brun S, Courtieu C, Biron C, Hoffet M, Hédon B, Marès P. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 1997;77:1096-1103. (Pubitemid 27311976)
20. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerck PJ. Development of a genotipe 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23:1122-1127. (Pubitemid 36713571)
21. Harper J, Coonen E, De Rycke M, Fiorentino F, Geraedts J, Goossens V, Harton G, Moutou C, Pehlivan Budak T, Renwick P. et al. What next for preimplantation genetic screening (PGS)? A position statement from the ESHRE PGD Consortium Steering Committee. Hum Reprod 2010; 25:821-823.
22. He S, Bremme K, Blombäck M. A laboratory method for determination of overall haemostatic potential in plasma I. Method design and preliminary results. Thromb Res 1999;96:145-156. (Pubitemid 29502215)
23. ′region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001;97:2053-2058. (Pubitemid 32239086)
24. International Committee for Monitoring Assisted Reproductive Technology (ICMART). World collaborative report on assisted reproductive technology, 2002. Hum Reprod 2009;24:2310-2320.
25. Kaandorp SP, Goddijn M, van der Post JAM, Hutten BA, Verhoeve HR, Hamulyak K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DNM.et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010;362:1586-1596.
26. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, Kingdom JC, Barrett J, Gent M. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomised controlled HepASA trial. J Rheumatol 2009;36:279-287.
27. Li TC, Makris M, Tomsu M, Tuckerman E, Laird S. Recurrent miscarriage: aetiology, management and prognosis. Hum Reprod Update 2002;8:463-481. (Pubitemid 35175207)
28. Lisman T, Leebek FWG, Meijer K, Van Der Meer J, Nieuwenhuis K, De Groot P. Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 2002;35:616-621. (Pubitemid 34183966)
29. Lisman T, deGroot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk for venous thrombosis. Blood 2005; 105:1102-1105. (Pubitemid 40170881)
30. Margalioth EJ, Ben-Chetrit A, Gal M, Eldar-Geva T. Investigation and treatment of repeated implantation failure following IVF-ET. Hum Reprod 2006;21:3036-3043. (Pubitemid 44811601)
31. Mart́nez-Zamora MA, Creus M, Tassies D, Bové A, Reverter JC, Carmona F, Balasch J. Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome. Fertil Steril 2010 94. 2437-2440.
32. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol 2009;145:121-127.
33. Meltzer ME, Lisman T, De Groot PG, Meijers JCM, Le Cessie S, Doggen CJM, Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010;116:113-121.
34. 2-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007;5:812-817. (Pubitemid 46563582)
35. Nyboe Andersen A, Goossens V, Bhattacharya S, Ferraretti AP, Kupka MS, de Mouzon J, Nygren KG; European IVF-monitoring (EIM) Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology and intrauterine inseminations in Europe, 2005: results generated from European registers by ESHRE: ESHRE.
36. The European IVF Monitoring Programme (EIM), for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod 2009;24:1267-1287.
37. Ola B, Li TC. Implantation failure following in-vitro fertilization. Curr Opin Obstet Gynecol 2006;18:440-445. (Pubitemid 43964773)
38. Practice Committee of Society for Assisted Reproductive Technology and the Practice Committee of American Society for Reproductive Medicine. Preimplantation genetic testing: a Practice Committee opinion. Fertil Steril 2008;90:S136-S143.
39. Puerto B, Creus M, Carmona F, Civico S, Vanrell JA, Balasch J. Ultrasonography as a predictor of embryo implantation after in vitro fertilization: a controlled study. Fertil Steril 2003;79:1015-1022. (Pubitemid 36385030)
40. Quenby S, Nik H, Innes B, Lash G, Turner M, Drury J, Bulmer J. Uterine natural killer cells and angiogenesis in recurrent reproductive failure. Hum Reprod 2009;24:45-54.
41. Rai R. Is miscarriage a coagulopathy? Curr Opin Obstet Gynecol 2003; 15:265-268. (Pubitemid 36677335)
42. Regan L, Rai R. Thrombophilia and pregnancy loss. J Reprod Immunol 2002; 55:163-180. (Pubitemid 34626161)
43. Sebire NJ, Backos M, El Gaddal S, Goldin RD, Regan L. Placental pathology, antiphospholipid antibodies, and pregnancy outcome in recurrent miscarriage patients. Obstet Gynecol 2003;101: 258-263. (Pubitemid 36170126)
44. Sotiriadis A, Makrigiannakis A, Stefos T, Paraskevaidis E, Kalantaridou SN. Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis. Obstet Gynecol 2007;109:1146-1155. (Pubitemid 46685960)
45. Stern C, Chamley L. Antiphospholipid antibodies and coagulation defects in women with implantation failure after IVF and miscarriage. Reprod Biomed Online 2006;13:29-37. (Pubitemid 44054843)
46. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998;273:27176-27181. (Pubitemid 28500426)
47. Wichers IM, Tanck MW, Meijers JC, Lisman T, Reitsma PH, Rosendaal FR, Büller HR, Middeldorp S. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thromb Haemost 2009; 101:465-470.
48. Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cośn R, Estellés A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 2008;15:923-929. (Pubitemid 351736413)